Design, synthesis and biological evaluation of some novel substituted quinazoline derivatives as antitumor agents.
Languages of publication
New series of 6,8-dibromo-2-(4-chlorophenyl)quinazolin-4-yloxy derivatives were synthesized and their cytotoxic activity on MCF7, HEPG2 and HCT116 cell lines were evaluated. Compound XI and XIIIb were two times more active than doxorubicin on MCF7 cancer cell line. Compound VIIIa was 3 times more active than doxorubicin on HEPG2 cancer cell line. While compounds XII, XIIIa and XIIIb were more potent than doxorubicin on HCT116 cancer cell line. IC50 of all newly synthesized compounds were evaluated in vitro for thier inhibition to EGFR tyrosine kinase. All compound show good inhibitory activity on EGFR tyrosine kinase with IC50 range (6.19-19.87) µM.
Publication order reference